- $1.07bn
- $380.13m
- $682.16m
- 50
- 31
- 37
- 33
Annual cashflow statement for Novavax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -418 | -1,744 | -658 | -545 | -187 |
| Depreciation | |||||
| Non-Cash Items | 359 | 320 | 574 | 167 | 3.26 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 12 | 1,734 | -361 | -377 | 48.5 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -42.5 | 323 | -416 | -714 | -87.3 |
| Capital Expenditures | -54.6 | -57.5 | -93 | -53.8 | -13.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -323 | 158 | 0 | -5.04 | -191 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | -378 | 100 | -93 | -58.8 | -204 |
| Financing Cash Flow Items | -39.1 | — | -5.26 | -3.59 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 985 | 462 | 325 | 4.47 | 261 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 567 | 880 | -179 | -765 | -38.5 |